mTOR Signaling in Metabolism and Cancer

• Other Authors: Huang, Shile (Editor)
• Format: Electronic Book Chapter
• Language: English
• Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Subjects: Medicine; mTOR; histone deacetylase; prostate cancer; integrins; adhesion; invasion; cell metabolism; T cells; Foxp3; Acute Lymphoblastic leukemia; targeted therapy; metabolism; cell signalling; mTOR signalling; head and neck cancer; mutant genes; biomarkers; targeted therapies; clinical trials; cancers; inhibitors; photodynamic therapy; PI3K; Akt; skin cancers; phytochemicals; melanoma; basal cell carcinoma; squamous cell carcinoma; Merkel cell carcinoma; TNBC; eribulin; PI3K/AKT/mTOR; everolimus; combination; synergy; mTOR signaling; tissue regeneration; neuron; muscle; liver; intestine; hematologic malignancies; regulatory T cells; tumor
• Online Access: DOAB: download the publication; DOAB: description of the publication

The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in this Special Issue summarize the current understanding of the mTOR pathway and its role in the regulation of tissue regeneration, regulatory T cell differentiation and function, and different types of cancer including hematologic malignancies, skin, prostate, breast, and head and neck cancer. The findings highlight that targeting mTOR pathway is a promising strategy to fight against certain human diseases.